Fortis_L.jpg
Fortis Inc. Provides Standby Commitment to Caribbean Utilities Company, Ltd.
September 23, 2024 06:00 ET | Fortis
ST. JOHN'S, Newfoundland and Labrador, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) announced today that its wholly owned subsidiary...
Brunswick Logo w Tagline_Midnight Blue (002).jpg
Brunswick Corporation’s award-winning 2024 Cannes Yachting Festival includes new product announcements and leading market share
September 23, 2024 06:00 ET | Brunswick Corporation
CANNES, France, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Brunswick Corporation, (NYSE: BC), and many of its industry leading brands, wrapped up another successful Cannes Yachting Festival with leading...
Caledonia-gr.jpg
Caledonia Mining Corporation Plc: Fatal accident at Blanket Mine
September 23, 2024 02:00 ET | Caledonia Mining Corporation Plc
Caledonia Mining Corporation Plc reports an accident in Zimbabwe.
teva_RGB_JPEG.jpg
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024 01:00 ET | Teva Pharmaceutical Industries Ltd
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an...
teva_RGB_JPEG.jpg
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024 04:15 ET | Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
teva_RGB_JPEG.jpg
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET | Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
Brookfield-Blue-Pantone-540b.jpg
Brookfield Corporation Announces Results of Conversion of its Series 40 Preferred Shares
September 20, 2024 16:45 ET | Brookfield Corporation
BROOKFIELD, NEWS, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Brookfield Corporation (NYSE: BN, TSX: BN) today announced that after having taken into account all election notices received by the deadline for...
Screenshot 2023-08-14 at 12.41.46 PM.png
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
September 20, 2024 16:05 ET | iBio, Inc.
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended...
MTI-Square.jpg
Minerals Technologies Announces Participation in Gabelli Funds 2nd Annual PFAS Symposium
September 20, 2024 13:00 ET | Minerals Technologies Inc.
NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) announced participation in Gabelli Funds PFAS Symposium in New York City on Thursday, September 26, 2024. Minerals...
Transaction in Own Shares
September 20, 2024 12:36 ET | Shell plc
Transaction in Own Shares 20 September, 2024 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 20 September 2024 it purchased the following number of Shares for...